12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Company News  |  Deals

Bristol-Myers, Duke University deal

Bristol-Myers and the university's Duke Translational Medicine Institute will co-develop and co-implement the protocol for a Phase II trial of the pharma's BMS-986202 (formerly AM152) for idiopathic...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >